#USA #Woburn #Sirtex Medical #Y-90 Therapy #SIR-Spheres®

Sirtex Medical's DOORwaY90 Study: A New Benchmark in Hepatocellular Carcinoma Treatment

In a major advancement in the field of interventional oncology, Sirtex Medical has announced the groundbreaking results from its DOORwaY90 study, which demonstrates a remarkable 100% local control of tumors using SIR-Spheres®, a form of Y-90 radioembolization therapy. This pivotal study marks a significant reference point not just in the treatment of hepatocellular carcinoma (HCC), but also in the broader application of Y-90 therapy across various oncology cases.

Background of the DOORwaY90 Study

The DOORwaY90 study is the first prospective multicenter trial in the United States focusing on selective internal radiation therapy (SIRT) using personalized dosimetry in patients with unresectable HCC. The study has achieved outstanding outcomes, including a 90% complete response rate and a staggering 99% objective response rate, evaluated by blinded independent central review. Remarkably, all patients involved in the study responded to the treatment, leading to a 100% local tumor control, a result that is among the highest recorded in Y-90 therapy.

Long-Lasting Responses and Liver Function Maintenance

The responses observed during the study were not only remarkable but also durable. Approximately 75% of the patients maintained their responses for over six months, with an average duration of 295 days. This highlights the potential of SIR-Spheres Y-90 resin microspheres to facilitate lasting tumor responses while preserving liver function.

In addition, over 95% of patients exhibited stable liver function after 12 months, showcasing the ability of personalized dosimetry to achieve aggressive tumor reduction without compromising liver reserves. This is particularly crucial for patients with HCC, who often face limited treatment options due to the nature of their condition.

Expert Insights on the Findings

Dr. Armeen Mahvash, an interventional radiologist at MD Anderson Cancer Center and one of the lead investigators of the DOORwaY90 study, expressed his enthusiasm about the findings, stating, “These 12-month results demonstrate a consistency of response achievable with personalized dosimetry. The high complete response rate, durability, and maintenance of liver function observed in this study provide physicians with increased confidence in using radioembolization as a definitive treatment intent directed at the liver.”

Matt Schmidt, CEO of Sirtex Medical, echoed this sentiment, noting, “These results raise the bar on what physicians should expect from Y-90 therapy. With an overall response rate of 99% and 100% tumor control, DOORwaY90 illustrates that personalized dosimetry with SIR-Spheres can deliver results that challenge conventional approaches and expand the treatment possibilities for patients with unresectable HCC.”

Conclusion: A New Era in Treatment Options

The SIR-Spheres Y-90 resin microspheres stand as the only FDA-approved radioembolization therapy for treating both metastatic colorectal cancer to the liver and unresectable HCC in the United States. The implications of the DOORwaY90 study are profound and may reshape the landscape of treatment options available for patients battling unresectable liver cancers. As physicians continue to explore personalized medicine approaches, the innovative findings from this study will undoubtedly play a crucial role in the evolution of liver cancer therapies.

For additional information on SIR-Spheres and the incorporation of personalized dosimetry into clinical practice, interested parties can connect with Sirtex at their official website.

• ---

Disclaimer: The federal law in the USA restricts the sale of this device to physicians or on their order. Common side effects include abdominal pain, nausea, and constipation. A complete list of side effects, warnings, and precautions can be found on the Sirtex website.